Evidence map›Paper›PMID 37873465›Full record

ArticlebioRxiv : the preprint server for biology2025

Programming megakaryocytes to produce engineered platelets for delivering non-native proteins.

Farhana Islam, Shwan B Javdan, Mitchell R Lewis, James D Craig, Han Wu, Tara L Deans

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Farhana IslamDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
Shwan B JavdanDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
Mitchell R LewisDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
James D CraigDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
Han WuDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
Tara L DeansDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0002-2361-2195
University of Utah · USGeorgia Institute of Technology · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Engineered platelets for the targeted destruction of circulating tumor cells - Administrative SupplementDP2CA250006 · NCI · UNIVERSITY OF UTAH · PI DEANS, TARA LYNN · 2019 to 2022
$2.4M
Engineering novel delivery systems with synthetic biologyR21EB025413 · NIBIB · UNIVERSITY OF UTAH · PI DEANS, TARA LYNN · 2018 to 2020
$609k
Amnis ImageStreamX MarkII Imaging Flow CytometerS10OD026959 · OD · UNIVERSITY OF UTAH · PI MARVIN, JAMES E · 2020 to 2020
$517k
Engineering Receptors to Control Platelet Activation and Therapeutic ReleaseF31HL167592 · NHLBI · UNIVERSITY OF UTAH · PI JAVDAN, SHWAN B · 2023 to 2023
$26k
NCI NIH HHS DP2 CA250006NCI NIH HHS P30 CA042014NHLBI NIH HHS F31 HL167592NIBIB NIH HHS R21 EB025413NIH HHS S10 OD026959
6 · The paper itself

Abstract

Platelets are anucleate cells naturally filled with secretory granules that store large amounts of protein to be released in response to certain physiological conditions. Cell engineering can endow platelets with the ability to deliver non-native proteins by modifying them as they develop during the cell fate process. This study presents a strategy to efficiently generate mouse platelets from pluripotent stem cells and demonstrates their potential as bioengineered protein delivery platforms. By modifying megakaryocytes, the progenitor cells of platelets, we successfully engineered platelets capable of packaging and delivering non-native proteins. These engineered platelets can offer flexible delivery platforms to release non-native proteins in a controlled manner upon activation when packaged into α-granules or deliver active enzymes to genetically alter recipient cells. Our findings highlight platelets as a promising tool for protein delivery in cell therapy applications.

Identifiers

PMID37873465
PMCPMC10592833
OpenAlexW4387648660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.